Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure.

Artificial organs·2026
Same author

Development of High-Affinity CHD1 Chromodomain Inhibitors.

Journal of medicinal chemistry·2026
Same author

Stabilizing Plasmodium falciparum proteins for small molecule drug discovery.

Protein science : a publication of the Protein Society·2026
Same author

Pentaphosphorylated magic spot nucleotides: chemoenzymatic synthesis and disassembly-based sensing.

Organic & biomolecular chemistry·2026
Same author

Enantioselective Rh/Cu-Catalyzed Addition of Terminal Alkynes to Allenes for the Synthesis of Chiral 1,4-Enynes.

Organic letters·2026
Same author

Lysine-specific histone demethylase 1a regulates nephron development and long-term transcriptional programming.

JCI insight·2026

Related Experiment Video

Updated: Sep 19, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.5K

Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity.

Sheng Wang1, Nicolas P F Barthes2, Sylvia Urban1

  • 1Klinik für Urologie und Zentrale Klinische Forschung, Klinikum der Albert-Ludwigs-Universität Freiburg, Freiburg 79106, Germany.

Journal of Medicinal Chemistry
|June 17, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed potent KMT9 inhibitors for cancer therapy. A prodrug form effectively inhibited colon cancer cell proliferation, validating KMT9 as a therapeutic target.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.4K

Related Experiment Videos

Last Updated: Sep 19, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.5K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.4K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Lysine methyltransferase 9 (KMT9) is a histone methyltransferase that monomethylates histone H4 at lysine 12 (H4K12me1).
  • KMT9 inhibition impairs the proliferation of various cancer cells, including prostate, lung, colon, and bladder cancers, indicating its therapeutic potential.

Purpose of the Study:

  • To develop potent and selective inhibitors of KMT9.
  • To validate KMT9 as a druggable target for cancer therapy.

Main Methods:

  • Structure-guided design of branched cofactor analogues with a methionine side chain.
  • Synthesis and characterization of KMT9 inhibitors.
  • Evaluation of inhibitor potency and selectivity.
  • Assessment of prodrug efficacy in colon cancer cell lines.

Main Results:

  • Branched cofactor analogues with methionine side chains were identified as highly potent KMT9 inhibitors.
  • Specific structural features, including a basic nitrogen and 4-chlorophenoxy-2-fluorobenzene, enhanced inhibitor potency and selectivity.
  • An ethyl ester prodrug (compound 8) demonstrated cellular target engagement.
  • The prodrug effectively blocked the proliferation of colon cancer cell lines.

Conclusions:

  • Pharmacological inhibition of KMT9 is a promising strategy for cancer therapy.
  • The developed prodrug demonstrates the potential of targeting KMT9 for cancer treatment.